Eriobotrya japonica hydrophilic extract modulates cytokines in normal tissues, in the tumor of Meth-A-fibrosarcoma bearing mice, and enhances their survival time

BMC Complementary and Alternative Medicine

Volumn 11, Issue , 2011, Pages

  Alshaker, Heba A ^a   Qinna, Nidal A ^a   Qadan, Fadi ^a   Bustami, Mona ^a   Matalka, Khalid Z ^a  

^a UNIVERSITY OF PETRA   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ANTINEOPLASTIC AGENT; CYTOKINE; ERIOBOTRYA JAPONICA EXTRACT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 17; PLANT EXTRACT; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; FEMALE; FIBROSARCOMA; FOLLOW UP; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LOQUAT; LUNG; MALE; MOUSE; NONHUMAN; PLANT LEAF; PROTEIN BLOOD LEVEL; SPLEEN; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; IMMUNOLOGY; MORTALITY;

ANIMALS; CYTOKINES; ERIOBOTRYA; FIBROSARCOMA; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED BALB C; PLANT EXTRACTS; PLANT LEAVES; TUMOR MICROENVIRONMENT;

EID: 79551579503     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-11-9     Document Type: Article

References (48)

1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727. 10.1038/nri1936, 16977338.
2. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275-293. 10.1111/j.0105-2896.2004.00199.x, 15546400.
3. Blankenstein T, Rowley DA, Schreiber H. Cytokines and cancer: experimental systems. Curr Opin Immunol 1991, 3:694-698. 10.1016/0952-7915(91)90098-L, 1755987.
4. Ito H, Kobayashi E, Takamatsu Y, Li SH, Hatano T, Sakagami H, Kusama K, Satoh K, Sugita D, Shimura S, Itoh Y, Yoshida. Polyphenols from Eriobotrya japonica and their cytotoxicity against human tumor cell lines. Chem Pharm Bull 2000, 48:687-693.
5. Ito H, Kobayashi E, Li SH, Hatano T, Sugita D, Kubo N, Shimura S, Itoh Y, Tokuda H, Nishino H, Yoshida T. Antitumor activity of compounds isolated from leaves of Eriobotrya japonica. J Agric Food Chem 2002, 50:2400-2403. 10.1021/jf011083l, 11929303.
6. Banno N, Akihisa T, Tokuda H, Yasukawa K, Taguchi Y, Akazawa H, Ukiya M, Kimura Y, Suzuki T, Nishino H. Anti-inflammatory and anti-tumor-promoting effects of the triterpene acids from the leaves of Eriobotrya japonica. Biol Pharm Bull 2005, 28:1995-1999. 10.1248/bpb.28.1995, 16204964.
7. Al-Hanbali M, Ali D, Bustami M, Abdel-Malek S, Al-Hanbali R, Alhussainy T, Qadan F, Matalka KZ. Epicatechin suppresses IL-6, IL-8 and enhances IL-10 production with NF-κB nuclear translocation in whole blood stimulated system. Neuro Endocrinol Lett 2009, 30:131-138.
8. Qa'dan F, Verspohl EJ, Nahrstedt A, Petereit F, Matalka KZ. Cinchonain Ib isolated from Eriobotrya japonica induces insulin secretion in vitro and in vivo. J Ethnopharmacol 2009, 124:224-227.
9. Lü H, Chen J, Li WL, Ren BR, Wu JL, Zhang HQ. Hypoglycemic effect of the total flavonoid fraction from Folium Eriobotryae. Phytomedicine 2009, 16:967-971.
10. Matalka KZ, Ali D, El Khawad A, Qa'dan F. The differential effect of Eriobotrya japonica hydrophilic leaf extract on cytokines production and modulation. Cytokine 2007, 40:235-240. 10.1016/j.cyto.2007.10.003, 18036829.
11. Matalka KZ, Tutunji MF, Abu-Baker M, Abu Baker Y. Measurement of protein cytokines in tissue extracts by enzyme-linked immunosorbent assays: Application to lipopolysaccharide-induced differential milieu of cytokines. Neuroendocrinol Lett 2005, 26:231-236.
12. Hirahara N, Nio Y, Sasaki S, Minari Y, Takamura M, Iguchi C, Dong M, Yamasawa K, Tamura K. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 2001, 61:79-89. 10.1159/000055357, 11474253.
13. Beatty GL, Paterson Y. IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ. J Immunol 2001, 166:2276-2282.
14. Pardali K, Moustakas A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007, 1775:21-62.
15. Podhajcer OL, Lopez MV, Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev 2007, 18:183-194. 10.1016/j.cytogfr.2007.01.014, 17320465.
16. Lee CH, Wu SL, Chen JC, Li CC, Lo HY, Cheng WY, Lin JG, Chang YH, Hsiang CY, Ho TY. Eriobotrya japonica leaf and its triterpenes inhibited lipopolysaccharide-induced cytokines and inducible enzyme production via the nuclear factor-κB signaling pathway in lung epithelial cells. Am J Chin Med 2008, 36:1185-1198. 10.1142/S0192415X0800651X, 19051345.
17. Kim S, Shin T. Anti-inflammatory effect of leaves of Eriobotrya japonica correlating with attenuation of p38 MAPK, ERK, and NF-κB activation in mast cells. Toxicol in Vitro 2009, 23:1215-1219. 10.1016/j.tiv.2009.07.036, 19665545.
18. Kojima H, Aizawa Y, Yanai Y, Nagaoka K, Takeuchi M, Ohta T, Ikegami H, Ikeda M, Kurimoto M. An essential role for NF-κB in IL-18-induced IFN-γ expression in KG-1 cells. J Immunol 1999, 162:5063-5069.
19. Reise Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004, 16:27-34. 10.1016/j.smim.2003.10.004, 14751761.
20. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999, 96:1036-1041. 10.1073/pnas.96.3.1036, 15346, 9927689.
21. Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reise Sousa C. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000, 13:453-462. 10.1016/S1074-7613(00)00045-5, 11070164.
22. Lund FE. Cytokine-producing B lymphocytes - key regulators of immunity. Curr Opin Immunol 2008, 20:332-338. 10.1016/j.coi.2008.03.003, 2474694, 18417336.
23. Theiner G, Rössner S, Dalpke A, Bode K, Berger T, Gessner A, Lutz MB. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol 2008, 45:244-252. 10.1016/j.molimm.2007.02.021, 17599410.
24. Lieberman LA, Hunter CA. Regulatory pathways involved in the infection-induced production of IFN-γ by NK cells. Microbes Infect 2002, 4:1531-1538. 10.1016/S1286-4579(02)00036-9, 12505525.
25. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146. 10.1038/nri1001, 12563297.
26. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 2007, 19:39-45. 10.1016/j.coi.2006.11.007, 17129718.
27. Zaas AZ, Schwartz DA. Innate immunity and the lung: defense at the interface between host and environment. Trends Cardiovasc Med 2005, 15:195-202. 10.1016/j.tcm.2005.07.001, 16182128.
28. Suzuki T, Chow CW, Downey GP. Role of innate immune cells and their products in lung immunopathology. Int J Biochem Cell Biol 2008, 40:1348-1361. 10.1016/j.biocel.2008.01.003, 18272422.
29. Armstrong L, Medford AR, Uppington KM, Robertson J, Witherden IR, Tetley TD, Millar AB. Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. Am J Respir Cell Mol Biol 2004, 31:241-245. 10.1165/rcmb.2004-0078OC, 15044215.
30. Kalvakolanu DV. Alternate interferon signaling pathways. Pharmacol Ther 2003, 100:1-29. 10.1016/S0163-7258(03)00070-6, 14550502.
31. Chen J, Liu X. The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications. Cell Immunol 2009, 254:85-90. 10.1016/j.cellimm.2008.09.001, 18848698.
32. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282:20059-20063. 10.1074/jbc.R700016200, 17502367.
33. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999, 397:710-713. 10.1038/17826, 10067896.
34. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584. 10.1038/nature02006, 14534577.
35. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
36. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26:579-591. 10.1016/j.immuni.2007.03.014, 17481928.
37. Correa SG, Maccioni M, Rivero VE, Iribarren P, Sotomayor CE, Riera CM. Cytokines and the immune-neuroendocrine network: What did we learn from infection and autoimmunity?. Cytokine Growth Factor Rev 2007, 18:125-134. 10.1016/j.cytogfr.2007.01.011, 17347025.
38. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234. 10.1038/nature04754, 16648837.
39. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189. 10.1016/j.immuni.2006.01.001, 16473830.
40. Qin Z, Kim HJ, Hemme J, Blankenstein T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon receptor-dependent foreign body reaction. J Exp Med 2002, 195:1479-1490. 10.1084/jem.20011887, 2193538, 12045246.
41. Masuda E, Shishido T, Fujimoto R, Maeda H. Changes in cellular composition induced by neocarzinostatin pretreatment in Meth A-bearing mice and the responsible antitumor effector cells. Immunopharmacology 1997, 37:105-116. 10.1016/S0162-3109(97)00040-4, 9285249.
42. Nair RE, Kilinc MO, Jones SA, Egilmez NK. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J Immunol 2006, 176:7325-7334.
43. Takeuchi A, Kamiryou Y, Yamada H, Eto M, Shibata K, Haruna K, Naito S, Yoshikai Y. Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4. Int Immunopharmacol 2009, 9:1562-1567. 10.1016/j.intimp.2009.09.012, 19788935.
44. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008, 68:3915-3923. 10.1158/0008-5472.CAN-08-0206, 2586596, 18483277.
45. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4(11):e7965. 10.1371/journal.pone.0007965, 2775953, 19956757.
46. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359. 10.1182/blood-2008-09-177360, 2714210, 19289853.
47. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111. 10.1038/35074122, 11323675.
48. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD. Interferon-γ and cancer immunoediting. Immunol Res 2005, 32:231-245. 10.1385/IR:32:1-3:231, 16106075.